318 Index Name Paper ref. Name Paper ref. Bass, R W10.3 Bastholm, P Mon 371 Bastien, O Mon 193 Bastos, R Tue 123 Bastrigin, D Tue 150 Batacchi, P Mon 120 Bate, A FC04.2.1 Bateman, J W03.7 Bathgate, R W14.2 Batista, MT Mon 291 Batista, V Thu 366 Battaglia, G Wed 400 Baudouin, V FC10.5.5 Bauer, C FC03.2.4 Bauer, HW Tue 214 Bauer, J Thu 267, Wed 252 Bauer, R FC16.2.2, Mon 153 Baun, M Wed 220 Baveewo, S FC01.4.5 Baw, B Wed 013 Bayat, M Thu 391 Baydan, E Wed 312 Baydemir, C Wed 421 Baydemýr, C Wed 420 Baydoun, A Thu 290 Bayever, D Tue 110 Bay-Jensen, A-C W26.2, W26.4 Baykov, A Wed 205 Bayliss, DA FC03.4.4 Bazarbachi, A FC01.3.4 Beart, P Mon 045 Beauchamp, GK W02.1.1 Beauchesne, M-F FC04.1.5 Beausejour, CM Tue 396 Beaussier, H Mon 191 Becemberg, IL Wed 024 Bech Thorsen, L Wed 240 Becic, F Wed 199 Beck, J Wed 094 Beck, L Thu 259 Becker, AJ Mon 247 Becker, E-M Thu 091 Beck-Nielsen, H FC05.4.4 Becquemont, L FC13.5.5, W02.2.6, Tue 189, FC02.2.6 Bedi, G FC14.3.4 Beetens, J Tue 280 Begg, E FC10.5.3 Begg, EJ Tue 322, Mon 064 Begovic, B Wed 171 Beh, J Tue 196 Beheshti, S Mon 455 Behrends, S Wed 280, Thu 252, Wed 210 Behr-Roussel, D FC08.1.1, Mon 233, Mon 232 Beiraghdar, F Thu 311 Beitnere, U Mon 429 Bejarano, I Mon 407 Bek, T Wed 229 Bekarev, A Tue 167 Bekhit, AA Tue 264 Bekker, Z Mon 258 Bektas, N Wed 303 Bel, L Tue 171 Belanger, F Tue 051 Beleslin-Cokic, B Wed 103 Beleznai, TZ Wed 206 Belkhiria, M-N Mon 006 Bellido, I Mon 471, Mon 149, Tue 394, Wed 005, Wed 007, Mon 123 Bellido, MV Wed 005 Bellien, J Thu 242 Bellien, J Wed 207 Belyakova, G Thu 114 Benameur, T Mon 148 Ben-Attia, M Mon 338 Bendayan, R FC02.4.5, Mon 070 Bender, B Mon 401 Bendhack, L Wed 198, FC15.4.5 Benedito, S Mon 239, Mon 411 Benemei, S Mon 120 Benetti, LR Mon 289 Bengtsson, F W29.1 Bengtsson, T Wed 063 Benham, C Mon 086 Benhamou, PY Tue 268 Benhanifia, MEB Wed 313 Bénichou, J FC04.2.6, Mon 145, Mon 132 Benkõ, I Mon 150, Mon 167 Benkõ, K Mon 150, Mon 167 Bennett, BM Tue 385 Bennett, L Thu 393 Benoît, LG Tue 190 Bensaid, D Mon 021 Bensman, A FC10.5.5 Benter, I Mon 151 Bentley, D Mon 259 Bentzen, BH FC06.1.4, Wed 099 Benyhe, S Wed 050 Ben-Zvi, Z Mon 054 Beraud-Dufour, S FC17.2.5 Berdnikova, N Mon 344, Wed 314, Thu 114 Berendt, L Mon 345 Berényi, A Tue 442 Bérézovski, V Thu 237 Berger, K Tue 313 Berggren, P-O FC12.4.1 Bergman, J Mon 234 Bergman, P Mon 122 Bergman, U W35.4, Mon 129, Tue 308, Wed 138 Bergmann, JF FC01.4.4 Bergmann, J-F Tue 188, Tue 189 Bergmann, TK Tue 395, Wed 151 Bergougnan, L Thu 215 Bergquist, K FC14.3.3 Bergqvist, L Wed 006, Thu 003 Berisa, A Mon 254 Berkman, K Mon 117 Bernabé, J Mon 233 Bernhard, D Wed 234 Bernhard, F YI.02 Berrue, F Wed 316 Bertilsson, L Tue 489, Tue 308, Mon 018 Wed 147 Bertin, F Thu 273 Bertoni, S Tue 258, Mon 381 Bertran, F Mon 362 Bertrand, H-O FC11.3.6
Name Paper ref. Name Paper ref. Bessac, A-M Tue 171 Besson, M Mon 337 Bethell, D Tue 090 Bettler, B FC11.3.5, Thu 028 Beubler, E Mon 369 Beugels, IPE Mon 212 Beukers, MW FC11.4.6 Beuve, A Thu 202 Bevan, S Mon 287 Beyens, MN FC04.2.5 Bhala, N W18.4 Bhanot, S Tue 148 Bharti, D Mon 336 Bhat, SJS Wed 172 Bhatia, J Mon 260, Wed 315, Wed 358 Bhatia, VK Thu 026 Bhosale, A Mon 336 Bhosale, AV Thu 363 Bhupathyraaj, M Tue 152 Bi, K Tue 130 Bi, Y-Q FC16.5.5 Biazzotto, J Wed 198, FC15.4.5 Bibby, BM Tue 359 Biddie, SC FC18.4.2 Bie, P FC06.2.5 Bielen, L FC01.3.7, Mon 135, Mon 373, Tue 328 Biermann, J Wed 099 Bieth, B Tue 196 Bihari, P FC16.1.5 Biliczki, P Mon 100 Billesbølle, CC Mon 073 Billing Jr., CB Wed 193 Bilsen, M FC18.2.5 Binder, A W03.6 Binder, EB FC17.5.1 Bindslev, N FC02.2.5, FC07.1.5, Mon 071 Birk, B FC18.2.6 Bischof, L Mon 045 Bishnoi, M Mon 183 Bisogno, A Tue 487, Mon 448, Tue 488, Mon 449 Bissantz, C Wed 094 Bissoli, F FC04.2.6, Mon 141 Bistawros, AA Tue 264 Bitay, M Wed 197 Bitel, M Mon 181 Bittner, RE Mon 218 Bjarnason, NH Mon 346 Bjerregaard, BK Mon 121 Bjerrum, L FC13.1.5 Bjerrum, OJ Mon 089 Björk, Susann Wed 028 Björkhem-Bergman, L Tue 383, Mon 122 Blad, CC FC11.2.5 Blagojevic, D Thu 329, Tue 122, Thu 318, Wed 387 Blais, Lucie FC04.1.5 Blaise, S Thu 244, Wed 208, Thu 245 Blakely, R FC02.4.1 Blakemore, D FC05.3.6 Blalock, JE FC09.5.2, FC09.5.3 Blanchard, SC FC02.1.2 Blanco, E Mon 123, Mon 149, Mon 471, Wed 007, Thu 187 Blanco-Rivero, J Wed 201 Blank, MD Wed 172 Blankesteijn, MW Wed 085 Blasio, A FC18.4.6 Blättermann, S FC11.1.6 Blayden, C FC03.2.1 Blazer, L YI.01 Blazsó, G Mon 261 Blin, P Mon 140 Bloch, V Wed 191 Block, W Tue 049 Blockhuys, S Tue 280 Blume, LC Wed 029 Boari, G Thu 251 Bobadilla, RA Wed 209 Bobkiewicz-Kozlowska, T Mon 262, Thu 174, Thu 291 Bocan, T Tue 372 Bocca, M-L Mon 362 Bochorishvili, T Mon 192, Tue 174 Bock, E PL23 Bock, H Tue 151 Bock, P Tue 169 Bocos, C Tue 387 Bocsan, C Mon 438 Bocsan, IC Mon 417, Tue 481 Bode, C Wed 099 Bodo, L P16.281 Bodvarsdottir, T Tue 132 Boehlen, F Tue 305 Boekschoten, M FC18.2.5 Boerngen-Lacerda, R Wed 395 Boeuf-Cazou, O Mon 124 Boeynaems, J-M W10.3 Bogacz, A Thu 174 Bogdanov, B Tue 167 Bogdelis, A Thu 023 Bøgebo, R Wed 036 Bøgesø, K Mon 046 Bogoslovscaya, S Tue 129 Bohman, L Tue 489 Bohotin, C Mon 108 Boije af Gennäs, G Tue 433 Boizel, R Tue 268 Bölcskei, K Mon 110, Tue 078 Bomba, A Tue 423 Bonaccini, L Tue 446, Mon 391 Bonaterra, G Mon 317, Tue 462 Bonci, A FC14.3.1 Bond, CM Tue 109 Bonde, MM Thu 058 Bondiolotti, G Thu 111 Bondolfi, G Mon 160 Bongue, B Mon 124 Bonke, G Mon 064, Mon 047 Bonnabry, P Tue 305 Bonnefond, A Mon 161 Bonta, P FC18.2.4 Booranasubkajorn, S Thu 361 Boos, J FC10.4.5 Booth, L Wed 020, Mon 420 Børgesen, M Wed 447 Børglum, A FC13.3.6 Index 319
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271: FC16 Natural products: Past and fut
- Page 272 and 273: FC16 Natural products: Past and fut
- Page 274 and 275: FC16 Natural products: Past and fut
- Page 276 and 277: FC17 New approaches and targets in
- Page 278 and 279: FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371:
368 Index Name Paper ref. Name Pape
- Page 372 and 373:
370 Index Name Paper ref. Name Pape
- Page 374 and 375:
372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor